Integrated and patient-selected care facilitates completion of isoniazid preventive therapy in Eswatini

被引:1
|
作者
Adams, L., V [1 ]
Maseko, T. S. B. [2 ]
Talbot, E. A. [1 ,3 ]
Grande, S. W. [1 ,4 ]
Mkhontfo, M. M. [2 ]
Simetane, Z. Z. [2 ]
Achilla, A. A. [2 ]
Haumba, S. M. [2 ]
机构
[1] Geisel Sch Med Dartmouth, Room 219,1 Rope Ferry Rd, Hanover, NH 03755 USA
[2] Univ Res Co, Mbabane, South Africa
[3] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[4] Dartmouth Inst Hlth Policy Ex Clin Practice, Hanover, NH USA
来源
PUBLIC HEALTH ACTION | 2019年 / 9卷 / 04期
关键词
tuberculosis; HIV; IPT; TUBERCULOSIS TREATMENT; DECISION-MAKING; HIV; DISCLOSURE; ADHERENCE; DELIVERY; STIGMA; PEOPLE;
D O I
10.5588/pha.19.0038
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Setting: Five human immunodeficiency virus (HIV) care facilities in Eswatini. Objective: To identify critical factors that enabled persons living with HIV to successfully complete a 6-month course of isoniazid preventive therapy (IPT) provided through a choice of facility-based or community-based delivery, coordinated with antiretroviral therapy (ART) refills. Design: This was a mixed methods, retrospective cross-sectional study. Results: Between June and October 2017, we interviewed 150 participants who had completed IPT in the previous year. Fourteen participants did not recall being offered a choice, and were excluded from the analysis. Of the remaining 136, 56.6% were female and 64.7% chose facility-based care; the median age was 42.5 years. Most participants reported that having a choice was important to their treatment completion (87.7%) and that linking IPT and ART refills facilitated undergoing IPT (98.5%). Participants were knowledgeable about the benefits of IPT and valued the education received from their providers. Participants also reported a high rate of IPT disclosure (95%) to friends and family members. Conclusion: Offering patients a choice of IPT delivery, linking IPT with ART refills, emphasizing patient education and engagement with healthcare workers, and supporting disclosure of IPT are critical factors to enabling IPT completion. These interventions should be incorporated throughout Eswatini and in similar high tuberculosis and HIV burden settings.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 50 条
  • [31] Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data
    Karanja, Muthoni
    Kingwara, Leonard
    Owiti, Philip
    Kirui, Elvis
    Ngari, Faith
    Kiplimo, Richard
    Maina, Maurice
    Masini, Enos
    Onyango, Elizabeth
    Ngugi, Catherine
    PLOS ONE, 2020, 15 (12):
  • [32] Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources
    Lawn, Stephen D.
    Wood, Robin
    De Cock, Kevin M.
    Kranzer, Katharina
    Lewis, James J.
    Churchyard, Gavin J.
    LANCET INFECTIOUS DISEASES, 2010, 10 (07): : 489 - 498
  • [33] Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study
    Wambiya, Elvis Omondi Achach
    Atela, Martin
    Eboreime, Ejemai
    Ibisomi, Latifat
    BMJ OPEN, 2018, 8 (12):
  • [34] Point-of-Care C-Reactive Protein Testing to Facilitate Implementation of Isoniazid Preventive Therapy for People Living With HIV
    Yoon, Christina
    Davis, J. Lucian
    Huang, Laurence
    Muzoora, Conrad
    Byakwaga, Helen
    Scibetta, Colin
    Bangsberg, David R.
    Nahid, Payam
    Semitala, Fred C.
    Hunt, Peter W.
    Martin, Jeffrey N.
    Cattamanchi, Adithya
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (05) : 551 - 556
  • [35] Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study
    Ngugi, Serah Kajuju
    Muiruri, Peter
    Odero, Theresa
    Gachuno, Onesmus
    BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [36] Low completion rate for the 6-months course of isoniazid preventive therapy among people living with HIV, North Eastern Uganda, 2015-2017
    Eurien, Daniel
    Okethwangu, Denis
    Aliddeki, Dativa Maria
    Kisaakye, Esther
    Nguna, Joy
    Bulage, Lilian
    Mugerwa, Shaaban
    Ario, Alex Riolexus
    PAN AFRICAN MEDICAL JOURNAL, 2024, 48
  • [37] Low completion rate for the 6-months course of isoniazid preventive therapy among people living with HIV, North Eastern Uganda, 2015-2017
    Eurien, Daniel
    Okethwangu, Denis
    Aliddeki, Dativa Maria
    Kisaakye, Esther
    Nguna, Joy
    Bulage, Lilian
    Mugerwa, Shaaban
    Ario, Alex Riolexus
    PAN AFRICAN MEDICAL JOURNAL, 2024, 48
  • [38] Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study
    Serah Kajuju Ngugi
    Peter Muiruri
    Theresa Odero
    Onesmus Gachuno
    BMC Infectious Diseases, 20
  • [39] Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study
    Masanja Robert
    Jim Todd
    Bernard J. Ngowi
    Sia E. Msuya
    Angella Ramadhani
    Veryhel Sambu
    Isaya Jerry
    Martin R. Mujuni
    Michael J. Mahande
    James S. Ngocho
    Werner Maokola
    BMC Infectious Diseases, 20
  • [40] Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study
    Robert, Masanja
    Todd, Jim
    Ngowi, Bernard J.
    Msuya, Sia E.
    Ramadhani, Angella
    Sambu, Veryhel
    Jerry, Isaya
    Mujuni, Martin R.
    Mahande, Michael J.
    Ngocho, James S.
    Maokola, Werner
    BMC INFECTIOUS DISEASES, 2020, 20 (01)